Ups and Downs for Drug Stocks

The WSJ Health Blog reports on how more transparency at the FDA could cause volatility in drug stocks.   Under a law passed last year, the FDA is just beginning to post quarterly lists of drugs “that could, possibly, carry previously unreported side effects.”    The Health Blog notes the lists are just preliminary, but could cause market swings.

– SBS